article MEDITRA, an oral supplement containing the active ingredient metoprolol, is available in a range of forms for the treatment of chronic pain, including for the management of fibromyalgia.
The drug is a topical analgesic, but also has a number of medical applications.
For instance, its active ingredient, a metabolite of the painkiller fentanyl, can be used to treat chronic pain conditions such as fibromyalgia.
Its active ingredient also has therapeutic effects in other disorders such as asthma and epilepsy.
The manufacturer of the drug, BioMed, says it has a long track record of safety and efficacy, and is able to demonstrate that its use in chronic pain is safe.
The pharmaceutical company, which has a global clinical arm, is also investing heavily in its manufacturing and testing capabilities, and has invested in the company’s production facility in the Netherlands.
Its sales in the last year rose by 17 per cent to about $1.4 billion, which represents a 19 per cent increase over the same period last year.
The company said that it had been “actively involved in a number” of clinical trials involving patients with fibromyache and related conditions.
Its CEO, Michael Soderberg, said that the company was currently in talks with the Dutch government about launching its own clinical trials in chronic fibromyage, including one in which the drug is being used as an anti-cancer treatment.
The government in the country is currently assessing the efficacy and safety of its own trials, as it does for other medicines, but has not yet decided whether to approve the drug.
BioMed has raised $1 billion from a group of investors including Morgan Stanley, Kleiner Perkins, Goldman Sachs, and Union Square Ventures.